Yu Wenquan, Li Ertong, Lv Zhigang, Liu Ke, Guo Xiaohe, Liu Yuan, Chang Junbiao
College of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou, Henan 450001, P. R. China.
High & New Technology Research Center of Henan Academy of Sciences, Zhengzhou, Henan 450002, P. R. China.
ACS Med Chem Lett. 2017 May 1;8(6):682-684. doi: 10.1021/acsmedchemlett.7b00174. eCollection 2017 Jun 8.
A novel 2',3'-dideoxy-2'-α-fluoro-2'-β--methyl-6-methoxy guanosine () and its phosphoramidate prodrug () have been designed and synthesized. Their biological activity was evaluated in both cytotoxicity and cell-based HCV replicon assays. Neither compounds exhibited cytotoxicity up to the highest concentration tested (100 μM) in the Huh-7 cell line. The prodrug () displayed nanomolar level antiviral activity (EC = 0.39-1.1 μM) against the HCV genotype (GT) 1a, 1b, 2a, and 1b S282T replicons.
一种新型的2',3'-二脱氧-2'-α-氟-2'-β-甲基-6-甲氧基鸟苷()及其磷酰胺酯前药()已被设计并合成。在细胞毒性和基于细胞的丙型肝炎病毒(HCV)复制子测定中评估了它们的生物活性。在Huh-7细胞系中,直至测试的最高浓度(100μM),两种化合物均未表现出细胞毒性。前药()对HCV基因型(GT)1a、1b、2a和1b S282T复制子显示出纳摩尔水平的抗病毒活性(EC = 0.39 - 1.1μM)。